Jemperli (dostarlimab-gxly) has received accelerated approval from FDA for adult patients with mismatch repair deficient recurrent or advanced solid tumors, as determined by an FDA-approved test, that have progressed on or following prior treatment and who have no satisfactory alternative treatment options.
Elizabeth Comen originally set out to write a book about the wellness industry, but ended up writing a different book altogether.
